Science

We have undertaken a program of non-clinical research in collaboration with leading research institutions in Australia and the UK. These are focussed on understanding the biological mechanism(s) of OPAL A action at the molecular, cellular and skin levels; and at understanding the biological basis for the attractive safety profile of the product. The findings to date suggest that there are multiple bioactive molecules in OPAL A, which have multiple modes of action in bioactive debridement, wound repair and regeneration, anti-microbial activity and relief of pain.

The current centre of research is The Centre for Cutaneous Research, Blizard Institute, Barts & The London Hospital, Queen Mary College, University of London. The work is being directed by the Lead at the Centre, Professor Michael Philpott. The enzymatic work is being directed and supervised by Emeritus Professor Keith Brocklehurst.

The results to date are of great excitement to the scientists involved in the work. Indeed, Professor Brocklehurst, globally renowned for his work on cysteine proteinases, and particularly papain, has described some of the results as “remarkable and unexpected”.

These results cannot be further discussed as they comprise new patentable material and are thus strictly confidential.

At the May 2014 Australasian Wound & Tissue Repair Society and Australian Wound Management Association conferences Professor Mike Philpott, Dr Neil Rzechorzek, Professor Geoffrey Mitchell & Associate Professor Michael Woodward presented a poster entitled Cysteine Proteases May Play a Role in the Wound Healing Properties of OPAL A.

Because of the confidentiality of the results of the work at the Blizard Institute it is unlikely that any academic papers or more detailed public presentations will be prepared for some time.

The work at the Blizard Institute arose from findings in work undertaken by Proteomics International of Perth, directed by its founder and CEO, Dr Richard Lipscombe.

Two other members of the our Science Team are Professor Allison Cowin of The University of South Australia and Dr Fraser Russell of The University of the Sunshine Coast in Queensland.

Some of the results from The University of the Sunshine Coast are not confidential. Dr Russell and his colleagues at the University published a paper entitled Effect of the novel wound healing agent, OPAL A on leukotriene B4 production in human neutrophils and 5-lipoxygenase activity in the December 2011 edition of Wound Practice & Research.